Company news
Adherium Ltd. (ASX:ADR) news
Every Adherium Ltd. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Adherium enters into additional $1M short-term loan facility
August 17, 2026
Adherium Announces CEO Transition
July 28, 2026
Adherium - Investor Update
July 26, 2026
Results of Extraordinary General Meeting
June 18, 2026
Notice of Share Consolidation
May 20, 2026
Adherium Hailie Smartinhaler Quarter-to-Date Sales Update
March 10, 2026
Half Yearly Report and Accounts
February 27, 2026
Completion of Placement and Institutional Entitlement Offer
February 17, 2026
Placement and Accelerated Non-Renounceable Entitlement Offer
February 15, 2026
Equity Raising Investor Presentation
February 15, 2026
Trading Halt
February 15, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 30, 2026
Adherium exceeds CY2025 device shipment milestones
December 23, 2025
Adherium quarter to date sales update
December 15, 2025
Adherium reaches major milestone in Allergy Partners rollout
November 26, 2025
Adherium's Hailie® Smartinhaler® Chosen for Groundbreaking iCARE Study: Significant Adherence, Consistent Outcomes, and Global Health Sys...
September 16, 2025
iCARE Study Hailie Smartinhaler Improves Patient Adherence
September 15, 2025
New Data, iCARE Study: Hailie® Smartinhaler® Powers Unprecedented Medication Adherence in Patients with COPD and Asthma
September 15, 2025
Preliminary Final Report
August 29, 2025
Firm commitments received for institutional placement
August 4, 2025
Adherium Appoints Dawn Bitz as CEO
July 22, 2025
Successful Completion of Retail Component of ANREO
July 17, 2025
Replacement Prospectus
June 26, 2025
Successful Completion of Institutional Component of ANREO
June 26, 2025
Prospectus
June 24, 2025
Accel Non-Renounceable Entitlement Offer to raise up to $4m
June 24, 2025
$900K Capital Raise to Accelerate Smart Inhaler in US
May 19, 2025
Adherium Secures $2.6M to Advance Smart Inhaler in US
March 18, 2025
Management Change
October 29, 2024
AstraZeneca selected Adherium Smartinhaler for its study
May 23, 2024
Non-Renounceable Rights Issue Offer Completes
May 23, 2024
Placement and Entitlement Offer to raise up to $8.37 million
April 26, 2024
First Patient Enrolled in Major e-health Clinical Study
March 19, 2024
Adherium receives $1.5m Australian R&D Tax Rebate
March 6, 2024
New CEO Appointed - Dr Paul Mastoridis
January 31, 2024
Resignation of CEO
January 15, 2024
Notice of Annual General Meeting/Proxy Form
October 26, 2023
Annual Report to shareholders
August 30, 2023
Adherium SPP and Shortfall Offers Prospectus
November 17, 2022
Adherium secures $13.5m in placement commitments
September 16, 2022
Adherium signs UK distribution agreement with Helicon Health
June 14, 2022
Adherium to support Avillion sponsored clinical study
June 1, 2022
Adherium awarded US-based AZ clinical study supply contract
September 24, 2021
Target's Statement
June 28, 2021
Letter to Shareholders re takeover offer
June 16, 2021
Adherium submits next gen sensor for US FDA clearance
May 31, 2021
Replacement Bidders Statement
May 27, 2021
1st Supplementary Bidder's Statement(marked up replacement
May 27, 2021
Adherium announces new CEO and Board appointments
May 12, 2021
Adherium Directors' Statement re Takeover
May 10, 2021